



Clinically established biodegradable long acting injectables: An industry perspective

Christian Isalomboto Nkanga^{a,b,c}, Andreas Fisch^c, Mazda Rad-Malekshahi^d, Marieta Duvnjak Romic^c, Birgit Kittel^e, Thomas Ullrich^e, Jing Wang^c, Rui Werner Maçedo Krause^a, Sabine Adler^c, Twan Lammers^f, Wim E. Hennink^g, Farshad Ramazani^{c,*}

^a Center for Chemo- and Bio-Medicinal Research (CCBR), Department of Chemistry, Rhodes University, P.O. Box 94, Grahamstown 6140, South Africa

^b Faculty of Pharmaceutical Sciences, University of Kinshasa, B.P. 212, Kinshasa, XI, Democratic Republic of the Congo

^c Technical Research and Development, Novartis Pharma AG, Basel 4002, Switzerland

^d Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

^e Novartis Institute for Biomedical Research, Novartis Pharma AG, Basel 4002, Switzerland

^f Department of Experimental Molecular Imaging, RWTH Aachen University, Aachen, Germany

^g Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands

ARTICLE INFO

Article history:

Received 8 October 2020

Received in revised form 9 November 2020

Accepted 10 November 2020

Available online 14 November 2020

Keywords:

Long acting injectables

Extended release

Drug delivery

PLGA microparticles

Microspheres

Implants

In situ forming implants

Drug crystals

Oil-based formulations

Drug crystal suspensions

ABSTRACT

Long acting injectable formulations have been developed to sustain the action of drugs in the body over desired periods of time. These delivery platforms have been utilized for both systemic and local drug delivery applications. This review gives an overview of long acting injectable systems that are currently in clinical use. These products are categorized in three different groups: biodegradable polymeric systems, including microparticles and implants; micro and nanocrystal suspensions and oil-based formulations. Furthermore, the applications of these drug delivery platforms for the management of various chronic diseases are summarized. Finally, this review addresses industrial challenges regarding the development of long acting injectable formulations.

© 2020 Elsevier B.V. All rights reserved.

Contents

1.	Introduction	20
2.	Overview of strategies for development of long acting injectables	20
2.1.	Microencapsulation	20
2.2.	Preformed and in situ forming implants	22
2.3.	Molecular and particulate drug modification	22
2.3.1.	Molecular drug modification (prodrugs)	22
2.3.2.	Particulate drug modification (micro/nano drug crystals)	24
3.	Clinically established long acting parenteral formulations	25
3.1.	Long acting biodegradable polymeric systems for parenteral use	25
3.1.1.	PLGA-based long acting biodegradable systems	25
3.1.2.	Marketed non-PLGA long acting parenteral formulations	30
3.2.	Marketed oil-based long acting parenteral formulations	32
3.2.1.	Androcur Depot®	32

* Corresponding author.

E-mail address: farshad.ramazani@novartis.com (F. Ramazani).